Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Sep 16, 2022--
The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
The optic neuritis treatment market is expected to register a CAGR of 4.1% during the forecast period. Optic neuritis is inflammation of the optic nerve in which myelin covering is damaged by the inflammation, which typically results in blurred or dark vision. Some of the symptoms include pain, vision loss in one eye, visual field loss, loss of color vision, flashing or flickering lights with eye movements. Signs and symptoms of optic neuritis can be the first indication of multiple sclerosis or the disorder can occur later in the course of multiple sclerosis. Multiple sclerosis is a disease that causes inflammation and damage to nerves in the brain, as well as the optic nerve.
Optic neuritis disease can happen to anyone at any age, but most cases occur in women who are between the ages of 20 to 40. In addition, according to the Optic Neuritis Foundation Inc, an estimate of 15-20% of the people suffering from optic neuritis are likely to end up suffering from multiple sclerosis.
Rise in the geriatric population, increasing incidence of multiple sclerosis, and growing awareness about early detection of optic neuritis are the key driving factors of the optic neuritis treatment market.
Key Market Trends
The Steroidal Therapy Segment is Expected to Hold a Major Market Share in the Optic Neuritis Treatment Market
North America is Expected to Hold a Significant Share in the Market during the Forecast Period
North America is expected to hold a major market share in the global optic neuritis treatment market due to high disease prevalence, availability of reimbursement, and growing awareness among the population regarding multiple sclerosis and optic neuritis in this region and a study published in the Journal of Neurology stated that the annual incidence of optic neuritis in the United States is found to be around 5/1,000,000, with estimated prevalence 115/1,000,000. Furthermore, technological advancement and the launch of new treatment options, increasing healthcare spending, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
Key Topics Covered:
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Mallinckrodt Pharmaceuticals
6.1.3 Novartis AG
6.1.4 Teijin Pharmaceutical Limited
6.1.5 Biogen
6.1.6 Allergan PLC
6.1.7 Bristol-Myers Squibb Company
6.1.8 Healthy Life Pharma Private Limited
6.1.9 AdvaCare Pharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/gle8cu
View source version on businesswire.com:https://www.businesswire.com/news/home/20220916005300/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: OPTICAL HEALTH COVID-19
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 09/16/2022 09:18 AM/DISC: 09/16/2022 09:18 AM
http://www.businesswire.com/news/home/20220916005300/en